Tianling Chen, MDAcerta Pharma,
South San Francisco, CA, USA
Acalabrutinib vs Rituximab plus Idelalisib or Bendamustine by Investigator Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study
Paolo Ghia, MD, Andrzej Pluta, MD, Malgorzata Wach, MD, Daniel Lysak, MD, Tomas Kozak, MD, Martin Simkovic, MD, Polina Kaplan, MD, Iryna Kraychok, MD, Arpad Illes, MD, Javier de la Serna, MD, Sean Dolan, MD, Philip Campbell, MD, Gerardo Musuraca, MD, Abraham Jacob, MD, Eric J. Avery, MD, Jae Hoon Lee, MD, Tianling Chen, MD, Wei Liang, PhD, Priti Patel, MD, Wojciech Jurczak, MD
October 25, 2019 | November 2019 Vol 10, No 11
Acalabrutinib is a highly selective, potent, covalent Bruton tyrosine kinase inhibitor that has shown clinical benefit in patients with relapsed/refractory (RR) chronic lymphocytic leukemia (CLL).
Last modified: November 6, 2019